SGLT2抑制剂对的影响 脏移植患者有或没有糖尿病
Carmine Secondulfo1, Nicoletta Vecchione2, Dora Russo2
1Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy.
International journal of molecular sciences
|April 17, 2025
概括
-葡萄糖共传输体2抑制剂 (SGLT2i) 有效地增加水平在移植接受者 (KTRs),减少低血. 这种方法提供了超越的好处,而不会影响功能.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心血管医学 心血管医学
- 内分泌学 在内分泌学.
背景情况:
- 由于免疫抑制和功能障碍,移植接受者 (KTRs) 患有低磁血症很普遍.
- 口服 (Mg2+) 补充剂通常对KTR无效,吸收不良和副作用.
- -葡萄糖携带载体2抑制剂 (SGLT2i) 显示出在慢性病中增加血清Mg2+的潜力,但它们对KTR的影响尚未得到充分证实.
研究的目的:
- 评估SGLT2抑制剂 (达帕格利弗洛辛) 对血清水平在移植接受者 (KTRs) 的影响.
- 评估SGLT2i治疗的KTR中低磁性血的患病率及其与口服补充剂,糖尿病和利尿剂使用的相关性.
- 探索SGLT2i的其他好处,例如对体重,血压和功能的影响.
主要方法:
- 一项观察性研究涉及63名用达帕格利弗洛辛治疗的KTR.
- 血清Mg2+水平在基线和治疗后3个月和6个月被分析.
- 评估了低磁性血症的患病率,口服补充剂的疗效,糖尿病状况和利尿剂的使用.
主要成果:
- 在KTR患者中,SGLT2i疗法显著增加了血清Mg2+水平,无论糖尿病状况如何,降低了低磁血症的患病率.
- 口服补充剂与改善的血清Mg2+水平没有相关性,这表明有效性有限.
- 用达帕格利弗洛辛治疗导致体重,血压和血清尿酸的减少,对移植功能没有不利影响.
结论:
- SGLT2 抑制剂代表了一种有前途的治疗策略,用于管理KTRs中的低磁性血症.
- SGLT2i可以减少对无效的口服补充剂的需求,同时提供心血管和的好处.
- 需要进一步的研究来证实这些发现,并了解SGLT2i对KTRs平衡的作用背后的机制.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
128
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
128
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
136
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
136
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
113
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
113
01:27Glucose Transporters
22.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.2K
01:06Oral Hypoglycemic Agents: Glinides
109
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
109
01:22Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K